FORM 10-Q
UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
March 31, 2003
or
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission file number 1-5667
Cabot Corporation(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (617) 345-0100
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes X No
Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).Yes X No
Indicate the number of shares outstanding of each of the issuers classes of Common Stock, as of the latest practicable date.
As of April 30, 2003, the Company had 61,727,000 shares of CommonStock, par value $1 per share, outstanding.
TABLE OF CONTENTS
CABOT CORPORATION
INDEX
-2-
Part I. Financial Information
Item 1. Financial Statements
CABOT CORPORATIONCONSOLIDATED STATEMENTS OF INCOMEThree Months Ended March 31, 2003 and 2002
(In millions, except per share amounts)
UNAUDITED
The accompanying notes are an integral part of these financial statements.
-3-
CABOT CORPORATIONCONSOLIDATED STATEMENTS OF INCOMESix Months Ended March 31, 2003 and 2002(In millions, except per share amounts)
-4-
CABOT CORPORATIONCONSOLIDATED BALANCE SHEETSMarch 31, 2003 and September 30, 2002
(In millions)
-5-
(In millions, except for share amounts)
-6-
CABOT CORPORATIONCONSOLIDATED STATEMENTS OF CASH FLOWSSix Months Ended March 31, 2003 and 2002
-7-
CABOT CORPORATIONCONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS EQUITYSix Months Ended March 31, 2003
-8-
CABOT CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTSMarch 31, 2003UNAUDITED
-9-
CABOT CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)March 31, 2003UNAUDITED
-10-
-11-
-12-
-13-
-14-
-15-
CABOT CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)March 31, 2003
-16-
-17-
-18-
-19-
-20-
-21-
-22-
-23-
-24-
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
I. Critical Accounting Policies
The preparation of the Companys financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. Critical accounting policies are those that are central to the presentation of the Companys financial condition and results of operations and that require management to make estimates about matters that are highly uncertain. On an on going basis, the Company evaluates its policies and estimates. The Company bases its estimates on historical experience, current conditions and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Revenue Recognition and Accounts ReceivableThe Company primarily derives its revenue from the sale of chemical, tantalum and specialty fluids products. Other operating revenues include tolling, services and royalties received for licensed technology. The Companys revenue recognition policies are in compliance with Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements (SAB 101), which establishes the criteria that must be satisfied before revenue is realized or realizable and earned.
Revenue from product sales is typically recognized when the product is shipped and title and risk of loss have passed to the customer. The Company generally is able to ensure that products meet customer specification prior to shipment. Under certain multi-year supply contracts with declining prices and minimum volumes, Cabot recognizes revenue based on an estimated average selling price over the contract lives.
The Company prepares its estimates for sales returns and allowances, discounts, and rebates quarterly based primarily on historical experience updated for changes in facts and circumstances, as appropriate. If actual future results vary, the Company may need to adjust its estimates, which could have a material impact on earnings in the period of adjustment.
The Company maintains allowances for doubtful accounts for estimated losses resulting from the potential inability of its customers to make required payments. If the financial conditions of the Companys customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances might be required, which could materially affect future earnings. As of March 31, 2003, the allowance for doubtful accounts was $3 million.
Inventory ValuationThe cost of most raw materials, work in process, and finished goods inventories in the U.S. is determined by the last-in, first-out (LIFO) method. Had the Company used the first-in, first-out (FIFO) method instead of the LIFO method for such inventories the value of those inventories would have been $79 million higher as of March 31, 2003. The cost of other U.S. and all non-U.S. inventories is determined using the average cost method or the FIFO method.
In cases where the market value of inventories is below cost, the inventory is stated at market value. The Company writes down its inventories for estimated obsolescence or unmarketable inventory by an amount equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. Such write-downs have not historically been significant. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.
Valuation of Long-Lived AssetsThe Companys long-lived assets include property, plant, equipment, long-term investments, goodwill and other intangible assets. The Company reviews the carrying values of long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the fair value of the asset is less than the carrying value of the asset. The fair value of long-lived assets, other than goodwill, is based on undiscounted estimated cash flows at the lowest level
-25-
determinable. The Companys estimates reflect managements assumptions about selling prices, production and sales volume, costs, and market conditions over an estimate of the remaining operating period. If an impairment is indicated, the asset is written down to the estimated fair value.
The Company performs an annual impairment test for goodwill in accordance with Statement of Financial Accounting Standard (FAS) No. 142. The fair value of the assets including goodwill balances is based on discounted estimated cash flows. The assumptions used to estimate fair value include managements best estimates of future growth rates, capital expenditures, discount rates, and market conditions over an estimate of the remaining operating period. If an impairment exists, a loss to write down the value of goodwill is recorded.
Environmental CostsThe Company accrues environmental costs when it is probable that the Company has incurred a liability and the amount can be reasonably estimated. When a liability amount cannot be reasonably estimated, but a range can be reasonably estimated, the Company accrues the amount that reflects its best estimate within that range or the low end of the range if no estimate within the range is better. The amount accrued reflects the Companys assumptions about remediation requirements at the contaminated site, the nature of the remedy, the outcome of discussions with regulatory agencies and other potentially responsible parties at multi-party sites, and the number and financial viability of other potentially responsible parties. The availability of new information, changes in the estimates on which the accruals are based, unanticipated government enforcement action, or changes in applicable government laws and regulations could result in higher or lower costs. The Company does not reduce its estimated liability for possible recoveries from insurance carriers. Proceeds from insurance carriers are recorded when realized by the receipt of cash or a contractual agreement. As of March 31, 2003, the Company had $27 million reserved for various environmental matters.
Pensions and Other Postretirement BenefitsThe Company maintains both defined benefit and defined contribution plans for its employees. In addition, the Company provides certain health care and life insurance benefits for retired employees. The costs and obligations related to these benefits reflect the Companys assumptions related to general economic conditions, including interest rates, expected return on plan assets, and the rate of compensation increases for employees. Projected health care benefits reflect the Companys assumptions about health care cost trends. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease. Actual results that differ from the assumptions are generally accumulated and amortized over future periods and therefore affect the recognized expense and recorded obligation in such future periods.
Litigation and ContingenciesThe Company accrues a liability for litigation when it is probable that a liability will be incurred and the amount can be reasonably estimated. The estimated reserves are recorded based on the Companys best estimate of the liability associated with such matters or the low end of the estimated range of liability if the Company is unable to identify a better estimate within that range. Litigation is highly uncertain and there is always the possibility of an unusual result in any particular case that may have an adverse effect on the results of operations.
-26-
II. Results of Operations
Net sales and operating profit before taxes by segment are shown in Note N of the Consolidated Financial Statements.
Three Months Ended March 31, 2003 versusThree Months Ended March 31, 2002
Net income for the second quarter of fiscal 2003 was $23 million ($0.33 per diluted common share) compared to $26 million ($0.36 per diluted common share) in the same quarter a year ago. Included in this quarters results are special charges totaling $22 million ($0.21 per diluted common share). Included in the results for the second quarter of 2002 are special charges totaling $3 million ($0.03 per diluted common share).
Sales increased $116 million from $350 million last year to $466 million this year, with increases in both the Chemical and Supermetals Businesses. However, income from continuing operations before taxes decreased 19% from $37 million in the second quarter of fiscal 2002 to $30 million in the second quarter of fiscal 2003.
Sales for the Chemical Businesses (carbon black, fumed metal oxides, inkjet and aerogel businesses) increased 21%, from $292 million in the second quarter of fiscal 2002 to $352 million in second quarter of fiscal 2003. Operating profit decreased 23%, from $30 million in fiscal 2002 to $23 million in the second quarter of fiscal 2003. The decrease in operating profit was principally driven by reduced operating margins ($28 million), which was partially offset by improved volumes ($11 million) and favorable foreign exchange impacts ($10 million).
In carbon black during the second quarter of fiscal 2003, increases in raw material and operating costs continued to exceed price increases, causing margins to decline. The margin decline more than offset a $10 million benefit from foreign exchange translation related to the weakening U.S. Dollar, and profit, therefore, decreased by $5 million. Carbon black volumes improved by 1% compared to the second quarter of fiscal 2002, but the trend differed considerably by region. North American and European volumes decreased by 9% and 11% respectively, while South America and Asia Pacific volumes increased by 22% and 34%, respectively. The decreases in North America and Europe are the result of a combination of weak economic factors as well as a shift in tire manufacturing from developed regions, where costs are high, to lower cost developing countries. This shift in demand as well as strong domestic demand in parts of South America and Asia Pacific, particularly in China, drove the increases in those regions.
Volumes in the fumed metal oxides business increased by 9% while sales improved 13% in the second fiscal quarter of 2003 compared to the same quarter of 2002. Volumes improved in all key markets electronics, traditional silicone rubber, composites and adhesives, and the niche market. This was partly offset by lower pricing and higher operating costs, leading to a profit increase of $1 million compared to the second quarter of fiscal 2002.
Cabots inkjet colorants business continues to make progress with the growth of its existing commercial products and the development of new products. Increased volumes for the OEM, aftermarket and colors markets resulted in a 37% increase in volume for the business compared to the second quarter of fiscal 2002. The volume gain was offset by higher operating costs related to the transfer of manufacturing to a new manufacturing plant, as well as higher R&D costs. These factors led to an operating profit that was equal to that of the second quarter of fiscal 2002.
The Nanogels plant is undergoing an extended commissioning process that is taking longer than expected. Production of the Nanogel aerogel particle involves the development of a new manufacturing process with inherent start-up challenges. The impact of this delayed start-up is not material to the Company.
-27-
In the Supermetals business (formerly called the Performance Materials business) sales increased 123% from $48 million in the second quarter of fiscal 2002 to $107 million in the second quarter of fiscal 2003. Volumes were higher than the year ago quarter by 135% due to a combination of contracted tantalum powder, wire and intermediate product sales and some improvement in Asia Pacific volumes. Average selling prices declined compared to the same quarter last year due to the renegotiation of certain customer contracts during calendar year 2002, resulting in lower prices but extended contract terms. Operating profit for the segment increased $23 million versus the same quarter in fiscal 2002. Litigation is ongoing with one customer, AVX, which continues to purchase products in accordance with the terms of its supply agreement.
In accordance with the terms of the tantalum contracts with certain customers, the sales price of certain contracted volumes declined effective January 1, 2003. The Company has recognized revenue at the estimated average selling price over the life of the respective contracts. This resulted in a deferral of approximately $3 million of revenue and profit in the second quarter of fiscal year 2003, bringing the total year to date balance of deferred revenue to $10 million. These amounts will be recognized as revenue and profit over the remaining life of the contracts, extending through 2006.
Specialty Fluids sales in the second quarter of fiscal year 2003 were $4 million versus $6 million in the same quarter of last year. The segment reported a $2 million operating loss compared to a $1 million loss for the same period in 2002. During the second quarter of 2003, volumes declined by 25%, due to a lower industry-wide level of drilling activity, particularly in the UK sector of the North Sea. To date, cesium formate has been successfully used in a total of 64 completion and drill-in applications, most of which involved challenging high pressure, high temperature wells in the North Sea.
The special items of $22 million recorded in the second quarter of fiscal year 2003 consist of a $21 million impairment to the value of the Companys investment in Sons of Gwalia, an Australian mining company from which Cabot purchases tantalum ore; a $1 million impairment to the value of the Companys investment in Angus and Ross, a mining company conducting exploration for new tantalum reserves; and $1 million in corporate restructuring costs related to the elimination of certain positions. The Company also recorded $1 million related to insurance recovery receipts during the quarter. Included in the results for the second quarter of 2002 are special charges totaling $3 million related to the cancellation of an expansion project in the Supermetals plant in Boyertown, Pennsylvania and non-capitalizable transaction costs. The special charges in fiscal 2002 were associated with the February 2002 acquisition of the remaining 50% of the shares in Cabot Supermetals Japan from the Companys joint venture partner, Showa Denko KK.
Given recent volume trends and lower raw material costs in the Chemical Businesses, the Company is cautiously optimistic about the results for the remainder of the year in this segment. Similarly, while the global electronics markets continue to be weak, the Company will benefit from contractual agreements with customers in the Supermetals segment. Finally, the Company is beginning to see signs of increased activity in the oil drilling industry, and it is encouraged by the acceptance of its cesium formate fluid in the North Sea market.
Research and technical service spending remained consistent at $12 million for the second quarter of 2003 versus the second quarter of 2002. Selling and administrative expenses increased $7 million or 14%, from $51 million for the second quarter of fiscal 2002 to $58 million for the same period in 2003. The increase is attributable to a combination of incremental costs incurred for the Companys new ERP system as well as higher compensation costs, costs of the acquired Japanese tantalum business and unfavorable currency translation impacts on costs from the weakening of the U.S. dollar.
Interest and dividend income in the second quarter was $1 million less than in the same quarter last year due to a decrease in Cabots cash position and lower interest rates.
Interest expense increased by $1 million from the year ago quarter due to higher debt partly offset by a lower effective overall interest rate.
Income tax expense in the second quarter decreased from $10 million in 2002 to $6 million in the same period of 2003. This decrease was the result of the Company benefiting from a lower effective tax rate on continuing
-28-
operations of 25% in the second quarter of fiscal 2003 versus 28% for the same quarter of 2002, as well as a $7 million tax benefit recorded on the impairment of the investment in Sons of Gwalia. The Company expects its effective tax rate on pre-tax income from continuing operations before special items to be approximately 25% for fiscal 2003.
As described in Note I of this 10-Q, the Company has ongoing exposure to respirator related claims. The Company is currently in the process of negotiating a potential settlement, which could, for a potentially extended period of time, limit its liability for these claims to a fixed annual amount. In the opinion of the Company, although final disposition of these claims may impact Cabots results of operations in a particular period, they should not, in the aggregate, have a material adverse effect on Cabots financial position.
To date, the Companys operations in Asia have not been significantly affected by Severe Acute Respiratory Syndrome (SARS). At this time, however, it is impossible to predict the long-term implications of this epidemic on the Companys existing operations and future business development.
Six Months Ended March 31, 2003 versusSix Months Ended March 31, 2002
Net income for the first six months of fiscal 2003 was $57 million compared to $64 million for the first half of fiscal 2002. Included in these results for the first six months of 2003 are special charges totaling $22 million ($0.21 per diluted common share). Included in the results for the first six months of 2002 are special charges totaling $3 million ($0.03 per diluted common share).
Sales increased 21% from $727 million last year to $876 million this year due to higher pricing in the Chemical Businesses and to higher volume levels in Supermetals. These increases as well as lower Supermetals operating costs and benefits from foreign exchange translation were the primary drivers behind the increase in profitability.
Sales for the Chemical Businesses increased $84 million or 15%, from $577 million last year to $661 million this year. Operating profit decreased $10 million or 18%, from $57 million to $47 million. The decrease in profitability is primarily attributed to lower operating margins ($54 million), which was partially offset by improved volumes ($26 million) and favorable foreign exchange impacts ($18 million). The lower margins are due to a combination of rising raw material prices through the second half of fiscal year 2002 and the Companys inability to increase prices to fully offset these increases as well as higher manufacturing and administrative costs.
Cabot Supermetals sales were $203 million, a 56% increase from $130 million in the first six months of fiscal 2002. Operating profit increased 51% from $45 million in the first six months of last year to $68 million in the first six months of this year. Volumes were higher than the first six months of fiscal year 2002 due to a combination of contracted tantalum powder, wire and intermediate product sales and some improvement in Asia Pacific volumes. Average selling prices declined compared to the prior year period due to the renegotiation of certain customer contracts during calendar year 2002, resulting in lower prices but extended contract terms.
Specialty Fluids sales decreased by 53% for the six-month period ended March 31, 2003 as a result of a decrease in activity in the well drilling industry. Sales decreased from $15 million last year to $7 million this year. The operating results for Specialty Fluids were a loss of $3 million for the six month period of 2003 and break-even for the six month period of 2002. The decline in profit is due to the lower volumes and revenues in the period.
The special items of $22 million recorded in the first six months of fiscal year 2003 consist of a $21 million impairment to the value of the Companys investment in Sons of Gwalia, an Australian mining company from which Cabot purchases tantalum ore; a $1 million impairment to the value of the Companys investment in Angus and Ross, a mining company conducting exploration for new tantalum reserves; and $1 million in corporate restructuring costs related to the elimination of certain positions. The Company also recorded $1 million related to insurance recovery receipts during the period. Included in the results for the first six months of 2002 are special charges totaling $3 million related to the cancellation of an expansion project in the Supermetals plant in Boyertown, Pennsylvania and
-29-
non-capitalizable transaction costs. The special charges in fiscal 2002 were associated with the February 2002 acquisition of the remaining 50% of the shares in Cabot Supermetals Japan from the Companys joint venture partner, Showa Denko KK.
Research and technical service spending increased by $1 million during the first half of 2003, reaching $24 million versus $23 million in the first half of last year. Selling and administrative expenses increased $11 million from $99 million for the first six months of fiscal 2002 to $110 million spent in the first six months of this year. The increase is largely due to higher compensation costs and incremental costs related to the Companys new ERP system.
Interest income in the six months ended March 31, 2003 was $3 million less than in the same period last year due to a decrease in Cabots cash position. Lower interest rates further negatively impacted interest income.
Increased debt combined with a lower effective overall interest rate held interest expense for the first six months of fiscal 2003 at $14 million, which was approximately the same as the year ago period.
In the six month period ended March 31, 2003, other income and charges decreased from $3 million of income in the prior year to a $1 million charge in the current year. This decrease was primarily due to costs incurred with the refinancing of debt during the current year as well as a benefit from the forfeiture of incentive shares in the first six months of fiscal 2002, which were not as significant in the current year.
III. Cash Flow and Liquidity
During the first six months of the fiscal year, cash provided by operating activities totaled $56 million as compared to cash provided by operating activities of $45 million for the same period last year. The cash provided by operating activities during the first six months of fiscal 2003 was primarily related to net income, with additions for non-cash expenses, offset by increases in receivables and inventories. The increase in receivables was driven by timing of receipts in the Supermetals and Chemicals businesses and increased sales company-wide. The Company continuously assesses the creditworthiness of its customers and no material reserves have been recorded for specific customers. The cash provided by operating activities during the first six months of 2002 was essentially the result of net income offset by an increase in working capital, primarily related to the Supermetals business.
Capital spending for the first six months of fiscal 2003 was $49 million. The majority of capital spending was related to improving existing assets. Capital expenditures for fiscal 2003 are expected to total approximately $143 million and include expenditures for replacement projects, plant expansions, and the completion of projects started in fiscal 2002. Capital spending for the first six months of fiscal 2002 was $167 million. Of this amount, $89 million, net of $10 million in cash acquired, was related to the February 2002 purchase of the remaining 50% of Cabot Supermetals Japan, a joint venture at the time.
Cash used for financing activities was $39 million in the first six months of fiscal 2003 as compared to $51 million used during the same period last year. The majority of the financing activities related to payments of dividends, purchases of stock, and the refinancing of debt assumed in the February 2002 acquisition of Cabot Supermetals Japan. During the month of September 2002, Cabot repaid approximately $10 million of bank notes. This repayment was included in the consolidated fiscal 2003 results due to the one month lag in reporting. In October 2002, Cabot entered into a 9.3 billion yen ($78 million) term loan agreement to refinance the majority of the remaining debt assumed in the Cabot Supermetals Japan acquisition. With the proceeds, Cabot repaid all $25 million of the remaining bank notes and $47 million of the long-term debt at Cabot Supermetals Japan. The new term loan matures in 2006. During the six months ended March 31, 2002, the cash used in financing activities was larger than the same period of 2003 due to a greater amount of stock repurchases.
During May 2003, the Board of Directors authorized management to explore a number of European restructuring initiatives. These proposed initiatives, which are subject to certain regulatory approvals and consultation processes with Works Councils, include closure of Cabots carbon black manufacturing facility in Zierbena, Spain, the consolidation of administrative services for all European businesses in one shared service center, and the implementation of a consistent staffing model for all manufacturing facilities in Europe. In addition to these initiatives, the Company has decided to discontinue an energy project that was in process at Zierbena and at one other European carbon black manufacturing facility. The initiatives being discussed could result in a pre-tax charge to earnings of approximately $60 million over the next 18 to 24 months, of which approximately $30 million is expected to be recorded in the second half of fiscal year 2003. Total cash outlays related to the program over the 18 to 24 month period are expected to be approximately $25 million.
In November 2000, a Cabot subsidiary borrowed 150 million EURO ($162 million) under a three year loan maturing in November 2003. During February 2003, Cabot amended the original agreement to extend the maturity until November 2004.
-30-
Management expects cash on hand, cash from operations and present financing arrangements, including Cabots unused line of credit, to be sufficient to meet Cabots cash requirements for the foreseeable future.
On September 8, 2000, Cabots Board of Directors authorized the repurchase of up to 10 million shares of Cabots common stock. On May 10, 2002, Cabots Board of Directors increased the number of shares of the Companys common stock authorized for repurchase from 10 million shares to a maximum of 12.6 million shares. Cabot repurchased 0.3 million shares of common stock during the first six months of fiscal 2003 for $6 million. As of March 31, 2003, approximately 3 million shares remained available to be purchased under the current share repurchase authorization.
On an ongoing basis, Cabot reviews its outstanding insurance claims, some of which relate to disposed and discontinued businesses, for potential recovery. Various amounts have been recovered in prior periods and Cabot anticipates receiving additional amounts in future periods.
Cabot is a defendant, or potentially responsible party, in various lawsuits and environmental proceedings wherein substantial amounts are claimed or are at issue. During the next few years, Cabot expects to spend a significant portion of its $27 million environmental reserve in connection with remediation at various environmental sites. These sites are primarily associated with businesses divested in prior years.
IV. Recent Accounting Developments
In December 2002, the FASB issued FAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure, which amends FAS No. 123, Accounting for Stock-Based Compensation. FAS No. 148 provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. FAS No. 148 also requires more prominent and more frequent disclosure in the financial statements about the effects of stock-based compensation. The disclosure provisions of FAS No. 148 were adopted by Cabot as of December 31, 2002 and are included in Note J. Other provisions of this statement are effective for the September 30, 2003 fiscal year-end. Cabot is in the process of assessing the impact of FAS No. 148 on its fiscal 2003 consolidated financial statements.
In January 2003, the FASB issued Interpretation No. 46, Consolidation of Variable Interest Entities (FIN 46), which clarifies the application of Accounting Research Bulletin (ARB) No. 51, Consolidated Financial Statements. FIN 46 provides guidance on the identification of and financial reporting for entities over which control is achieved through the means other than by voting rights. FIN 46 determines whether such entities should be consolidated under the controlling interest financial model of ARB No. 51, the variable interest model of FIN 46 or other existing authoritative guidance. Cabot adopted FIN 46 as of January 31, 2003 for variable interest entities created after January 31, 2003 and will adopt FIN 46 on July 1, 2003 for variable interest entities that were created before January 31, 2003. Cabot is assessing the impact of FIN 46 on the consolidated financial statements.
In February 2003, the FASB issued Emerging Issues Task Force Issue 00-21, Accounting for Revenue Arrangements with Multiple Deliverables (EITF 00-21). EITF 00-21 provides guidance for the accounting by a vendor for arrangements involving multiple revenue-generating activities. The provisions of EITF 00-21 are effective for Cabot for the interim period beginning July 1, 2003. Cabot is in the process of assessing the impact of EITF 00-21 on the consolidated financial statements.
Forward-Looking Information: Included above are forward-looking statements relating to managements expectations of future profits, the possible achievement of the Companys financial goals and objectives and managements expectations for shareholder value creation initiatives and for the Companys product development program. Actual results may differ materially from the results anticipated in the statements included herein due to a variety of factors, including market supply and demand conditions, fluctuations in currency exchange rates, costs and availability of raw materials, patent rights of others, stock market conditions, demand for our customers products, competitors reactions to market conditions, the outcome of pending litigation and governmental investigations, the impact of global health and safety concerns on economic conditions or market opportunities and
-31-
other factors discussed in the Companys 2002 Annual Report on Form 10-K. Timely commercialization of products under development by the Company may be disrupted or delayed by technical difficulties, market acceptance, competitors new products, as well as difficulties in moving from the experimental stage to the production stage.
-32-
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As part of the Cabot Supermetals Japan acquisition, Cabot assumed variable rate debt that was economically hedged with interest rate swaps. In October 2002, Cabot refinanced the underlying variable rate debt and the interest rate swaps were terminated.
On October 29, 2002, Cabot entered into two interest rate swaps with an aggregate notional amount of 9.3 billion yen ($78 million). The swaps are variable-for-fixed swaps of the quarterly interest payments on related debt and mature in fiscal 2008. The swaps are derivative instruments as defined by FAS No. 133, Accounting for Derivative Instruments and Hedging Activitiesand have been designated as cash flow hedges. Changes in the value of the effective portion of cash flow hedges are reported in other comprehensive income, while the ineffective portion is reported in earnings. The change in fair value since inception has been nominal.
During the first quarter of fiscal 2003, Cabot began using both yen based debt and cross currency swaps to hedge its net investment in Japanese subsidiaries. On October 24, 2002, Cabot entered into a 9.3 billion yen ($78 million) three-year term loan agreement with a group of banks to refinance existing debt at Cabot Supermetals Japan. On November 20, 2002, Cabot entered into two cross currency swaps for an aggregate amount of $41 million. Upon maturity of the swaps, Cabot is entitled to receive $41 million U.S. dollars and is obligated to pay 5 billion Japanese yen. Cabot is also entitled to receive semi-annual interest payments on $41 million at 3 Month U.S. dollar LIBOR interest rates and is obligated to make semi-annual interest payments on 5 billion yen at 3 Month Japanese yen LIBOR interest rates. Included in liabilities at March 31, 2003 is $2 million related to the fair value of the cross currency swaps and $3 million related to the cumulative translation differences in Cabots yen denominated debt.
The debt and cross currency swaps have been designated as hedges of Cabots net investment in Japan and are accounted for under FAS No. 133. The effectiveness of these hedges is based on changes in the spot foreign exchange rates and the balance of Cabots yen denominated net investments. The change in value of the debt and of the cross currency swaps, totaling $5 million for the six month period ending March 31, 2003, has been recorded as a foreign currency translation loss in Accumulated Other Comprehensive Loss, offsetting foreign currency translation gains of Cabots yen denominated net investments. Net losses recorded in earnings, representing the amount of the hedges ineffectiveness for the period, were nominal.
Item 4. Controls and Procedures
Within the 90 days prior to the date of this report, the Company carried out an evaluation, under the supervision and with the participation of the Companys management, including the Companys Chairman of the Board, President and Chief Executive Officer, and its Executive Vice President and Chief Financial Officer, of the effectiveness of the Companys disclosure controls and procedures pursuant to Rule 13a-14 under the Securities Exchange Act of 1934, as amended. Based upon that evaluation, the Companys Chairman of the Board, President and Chief Executive Officer and its Executive Vice President and Chief Financial Officer concluded that the Companys disclosure controls and procedures are effective, in all material respects, with respect to the recording, processing, summarizing and reporting, within the time periods specified in the Securities and Exchange Commissions rules and forms, of information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act.
There were no significant changes in the Companys internal controls or in other factors that could significantly affect internal controls subsequent to the date of their last evaluation.
-33-
Part II. Other Information
Item 1. Legal Proceedings
Cabot has exposure in connection with a safety respiratory products business that a subsidiary acquired from American Optical Corporation (AO) in an April 1990 asset transaction. The subsidiary disposed of that business in July 1995. In connection with its acquisition, the subsidiary agreed, in certain circumstances, to assume that portion of liabilities, including the costs of legal fees together with the amounts paid in settlement or judgment, allocable to AO respiratory products used prior to the 1990 closing. In exchange for the subsidiarys assumption of pre-closing liabilities, AO agreed to provide to the subsidiary the benefits of: (1) AOs insurance coverage for the pre-closing period, and (2) another entitys private indemnity of AO holding it harmless from any liability allocable to AO respiratory products used prior to May, 1982. Generally, these respirator liabilities involve claims for personal injury, including asbestosis and silicosis, allegedly resulting from the use of AO respirators that were negligently designed or labeled.
Neither Cabot, nor its past or present subsidiaries, at any time manufactured asbestos or asbestos-containing materials or products. Moreover, not every person with exposure to asbestos giving rise to an asbestos claim used a form of respiratory protection. At no time did AOs respiratory product line represent a significant portion of the overall respiratory product market. In addition, other parties, including AO, AOs insurers, and another private indemnitor and its insurers (collectively, the Payor Group), incur significant portions of the costs of these liabilities, leaving Cabot with a portion of the liability in only some of the pending cases.
Cabots subsidiary disposed of the business in July 1995 by transferring it to a newly-formed joint venture called Aearo Corporation (Aearo). Cabot has a 40% equity interest in Aearo. Cabot agreed to have its subsidiary retain liabilities allocable to respirators used prior to the 1995 transaction so long as Aearo pays Cabot an annual fee of $400,000. Aearo can discontinue payment of this fee at any time, in which case it will assume the liability for, and indemnify Cabot against, the liabilities allocable to respirators manufactured and used prior to the 1995 transaction. Cabot has no liability in connection with any products manufactured by Aearo after 1995. Between July 1995 and September 30, 2001, Cabots total costs and payments in connection with these respirator liabilities did not exceed the total amounts Cabot received from Aearo. Since 1990, for those claims in connection with which Cabot has contributed toward the costs of defense and settlement, Cabot has contributed roughly $320 per claim, or approximately 10% of the total costs per claim paid by the Payor Group.
As of December 31, 2002, there were approximately 50,000 claimants in pending cases asserting claims against AO in connection with respiratory products, excluding the 13,000 Mississippi claimants discussed in the paragraph below. As of March 31, 2003, there were approximately 74,000 such claimants, also excluding the 13,000 Mississippi claimants. The vast majority of new claims since January 1, 2003 were filed in Mississippi and appear to have been prompted by changes in Mississippis state procedural laws. In the past, Cabot has contributed to the costs of a significant percentage, but not all, pending claims, depending on several factors, including the period of alleged product use.
During the third quarter of fiscal year 2002, Cabot agreed to pay up to $2 million as its contribution toward a settlement involving up to 13,000 claimants in Mississippi. As a result of the Mississippi settlement and the number of new claims that were filed during the first half of calendar year 2002, Cabot recorded a charge of $5 million during the third quarter of fiscal 2002, resulting in a total reserve for respirator matters of $6 million as of September 30, 2002. In estimating its liability at that time, Cabot made the following assumptions: (i) that costs to Cabot would continue at Cabots historical contribution rate of $320 per claimant; (ii) that Cabot would continue to contribute to only slightly more than half of the total pending claims; and (iii) that a significant number of the pending claims were included in the Mississippi settlement. This amount represented Cabots best estimate at that time of the liability it would incur in connection with pending respirator claims.
Cabot, at the time it agreed to contribute to the Mississippi settlement, expected to pay its $2 million contribution over a period of approximately eighteen months. Due to complications in the funding mechanism of the overall settlement of these Mississippi claims, a shortfall of $5.5 million in the initial amount to be paid to the plaintiff group resulted. In December 2002, Cabot agreed to fund this shortfall in exchange for an undertaking from representatives
-34-
of the Payor Group to exercise their best efforts to seek a global settlement with the Payor Group. While Cabots ability to negotiate an acceptable global settlement and its specific terms are uncertain at this time, the global settlement being discussed would provide that as long as the Payor Group continues to pay all costs and liabilities in connection with the respirator litigation, Cabots liability under a global settlement would be limited to a specified annual amount and would no longer be based on the historical allocation arrangements.
If a global settlement is not reached, disagreements among members of the Payor Group will make it unlikely that the allocation assumptions previously used by Cabot to determine the amount of the reserve will continue to apply. In addition, because this is a very unpredictable area, Cabot continues to be unable to estimate the number of future claims or the range of liability that may be incurred as a result of such claims on any reasonable basis. For these reasons, Cabot is currently unable to reasonably estimate a range of possible loss for pending and future respirator claims. As a result, Cabot has not recorded an additional reserve for these claims at this time. Although Cabots liability associated with these pending and future claims, or Cabots success in reaching a global settlement, could have a material effect on earnings in a particular quarter of fiscal year, Cabot continues to believe that its respirator exposure will not have a material adverse effect on Cabots financial position or liquidity.
In connection with the action brought by AVX Corporation against the Company in the United States District Court for the District of Massachusetts, AVX filed an amended complaint in February 2003. The amended complaint was dismissed for failure to support federal jurisdiction. Separately, Cabot filed an action against AVX in the Business Litigation Section of the Superior Court of Massachusetts seeking declaratory relief as to the validity of Cabots supply contract with AVX, as well as a declaration that Cabot is not in breach of an alleged prior agreement, and that Cabot did not engage in unfair and deceptive trade practices. Litigation between AVX and Cabot is now proceeding in the Superior Court of Massachusetts only. AVX has continued to purchase product in accordance with the terms of its contract during the dispute.
During and subsequent to the second fiscal quarter Cabot, Phelps Dodge Corporation, Columbian Chemicals Co., Degussa Engineered Carbons, LP, Degussa AG and Degussa Corporation (referred to collectively as the Defendants), were named in antitrust law suits filed by the following plaintiffs: Parker Hannifin, filed in US District Court for the Northern District of Ohio; Synaflex Rubber Products Co., filed in US District Court for the District of New Jersey; Alco Industries, Inc., filed in US District Court for the District of New Jersey; Chase & Sons, Inc., filed in US District Court for the District of New Jersey; Standard Rubber Products, filed in US District Court for the District of Massachusetts; and Reeves Brothers, filed in US District Court for the District of Massachusetts. The actions, all of which are similar to the action filed against the Defendants in January 2003 by Technical Industries, Inc. in US District Court for the District of Massachusetts, have been filed by the plaintiffs on their own behalf and on behalf of all individuals or entities who purchased carbon black in the United States directly from the Defendants from approximately 1999 until the present (the Class Period), and allege that the Defendants conspired to fix, raise, maintain or stabilize prices for carbon black sold in the United States during the Class Period. The plaintiffs seek treble damages and legal costs. None of the classes of plaintiffs in these cases have been certified. All parties have sought to transfer all pending cases into a single consolidated multi-district litigation forum pursuant to federal law, but no action on this request has been taken. Cabot believes it has strong defenses to these actions, which it intends to assert vigorously.
Cabot has various other lawsuits, claims and contingent liabilities arising in the ordinary course of its business, including a number of claims asserting premises liability for asbestos exposure. In the opinion of the Company, although final disposition of all of its suits and claims may impact Cabots results of operations in a particular period, they should not, in the aggregate, have a material adverse effect on Cabots financial position.
-35-
Item 4. Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders of Cabot Corporation (the Annual Meeting) was held on March 13, 2003. An election of directors was held for which John G.L. Cabot, John F. OBrien, Lydia W. Thomas and Mark S. Wrighton were nominated and elected to the class of Directors whose terms expire in 2006. The following votes were cast for or withheld with respect to each of the nominees:
Other Directors whose terms of office as Directors continued after the meeting are:
Item 6. Exhibits and Reports on Form 8-K
-36-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
-37-
CERTIFICATIONS
I, Kennett F. Burnes, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Cabot Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
b) evaluated the effectiveness of the registrants disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the Evaluation Date); and
c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrants other certifying officers and I have disclosed, based on our most recent evaluation, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions):
a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrants ability to record, process, summarize and report financial data and have identified for the registrants auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal controls; and
6. The registrants other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
-38-
I, John A. Shaw, certify that:
-39-